Bicalutamide (‘Casodex’) 150 mg in addition to standard care in patients with nonmetastatic prostate cancer: updated results from a randomised double-blind phase III study (median follow-up 5.1 y) in the early prostate cancer programme

被引：0
|
作者：
M Wirth
C Tyrrell
K Delaere
M Sánchez-Chapado
J Ramon
D M A Wallace
J Hetherington
F Pina
C Heyns
T Borchers
T Morris
J Armstrong
机构：
[1] Technical University of Dresden Medical School,Plymouth Oncology Centre
[2] Derriford Hospital,Department of Urology
[3] Atrium Medical Centre,Servico de Urologica
[4] Hospital Principe de Asturias,Tygerberg Hospital and Faculty of Health Sciences
[5] Alcala de Henares,undefined
[6] Chaim Sheba Medical Center,undefined
[7] Queen Elizabeth Medical Centre,undefined
[8] Princess Royal Hospital,undefined
[9] Hospital de São Joao,undefined
[10] University of Stellenbosch,undefined
[11] AstraZeneca,undefined
来源：
Prostate Cancer and Prostatic Diseases | 2005年 / 8卷
关键词：
nonsteroidal antiandrogen; prostatic neoplasms; clinical trial; bicalutamide;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
Trial 24 is one of three placebo-controlled trials within the ongoing bicalutamide (‘Casodex’†) Early Prostate Cancer (EPC) programme evaluating bicalutamide 150 mg/day in addition to radical prostatectomy, radiotherapy or watchful waiting for T1b–4, any N, M0 prostate cancer. In Trial 24, at 5.1 y median follow-up, the addition of bicalutamide significantly (P<0.0001) improved objective progression-free survival (PFS) and prostate-specific antigen PFS compared with standard care alone. There was no significant difference in overall survival (P=0.746). In the context of the whole EPC programme, long-term bicalutamide is not appropriate for localised disease, yet provides advantages in delaying disease progression in patients with locally advanced prostate cancer.
引用
收藏
页码：194 / 200
页数：6
相关论文
共 50 条
  • [1] Bicalutamide ('Casodex') 150 mg in addition to standard care in patients with nonmetastatic prostate cancer:: updated results from a randomised double-blind phase III study (median follow-up 5.1 y) in the early prostate cancer programme
    Wirth, M
    Tyrrell, C
    Delaere, K
    Sánchez-Chapado, M
    Ramon, J
    Wallace, DMA
    Hetherington, J
    Pina, F
    Heyns, C
    Borchers, T
    Morris, T
    Armstrong, J
    [J]. PROSTATE CANCER AND PROSTATIC DISEASES, 2005, 8 (02) : 194 - 200
  • [2] Bicalutamide (Casodex) 150 mg plus standard care in early non-metastatic prostate cancer: results from Early Prostate Cancer Trial 24 at a median 7 years' follow-up
    M Wirth
    C Tyrrell
    K Delaere
    M Sánchez-Chapado
    J Ramon
    D M A Wallace
    J Hetherington
    F Pina
    C F Heyns
    S Navani
    J Armstrong
    [J]. Prostate Cancer and Prostatic Diseases, 2007, 10 : 87 - 93
  • [3] Bicalutamide (Casodex) 150 mg plus standard care in early non-metastatic prostate cancer:: results from Early Prostate Cancer Trial 24 at a median 7 years' follow-up
    Wirth, M.
    Tyrrell, C.
    Delaere, K.
    Sanchez-Chapado, M.
    Ramon, J.
    Wallace, D. M. A.
    Hetherington, J.
    Pina, F.
    Heyns, C. F.
    Navani, S.
    Armstrong, J.
    [J]. PROSTATE CANCER AND PROSTATIC DISEASES, 2007, 10 (01) : 87 - 93
  • [4] Bicalutamide ('Casodex') 150 mg as adjuvant to radiotherapy in patients with localised or locally advanced prostate cancer: Results from the randomised Early Prostate Cancer Programme
    Tyrrell, CJ
    Payne, H
    See, WA
    McLeod, DG
    Wirth, MP
    Iversen, P
    Armstrong, J
    Morris, C
    [J]. RADIOTHERAPY AND ONCOLOGY, 2005, 76 (01) : 4 - 10
  • [5] Bicalutamide 150 mg in addition to standard care for patients with early non-metastatic prostate cancer:: updated results from the Scandinavian Prostate Cancer Period Group-6 Study after a median follow-up period of 7.1 years
    Iversen, Peter
    Johansson, Jan-Erik
    Lodding, Par
    Kylmala, Timo
    Lundmo, Per
    Klarskov, Peter
    Tammela, Teuvo L. J.
    Tasdemir, Ilker
    Morris, Thomas
    Armstrong, Jon
    [J]. SCANDINAVIAN JOURNAL OF UROLOGY AND NEPHROLOGY, 2006, 40 (06): : 441 - 452
  • [6] Bicalutamide 150 mg in addition to standard care in patients with early, non-metastatic prostate cancer: Results from the SPCG-6 study at a median follow-up of 5.3 years
    Iversen, P
    [J]. JOURNAL OF UROLOGY, 2004, 171 (04): : 311 - 312
  • [7] Casodex (bicalutamide) 150-MG monotherapy compared with castration in patients with previously untreated nonmetastatic prostate cancer: Results from two multicenter randomized trials at a median follow-up of 4 years
    Iversen, P
    Tyrrell, CJ
    Kaisary, AV
    Anderson, JB
    Baert, L
    Tammela, T
    Chamberlain, M
    Carroll, K
    Gotting-Smith, K
    Blackledge, GRP
    [J]. UROLOGY, 1998, 51 (03) : 389 - 396
  • [8] Bicalutamide 150 mg in addition to standard care in patients with localized or locally advanced prostate cancer: Results from the second analysis of the early prostate cancer program at median followup of 5.4 years
    Wirth, MP
    See, WA
    McLeod, DG
    Iversen, P
    Morris, T
    Carroll, K
    [J]. JOURNAL OF UROLOGY, 2004, 172 (05): : 1865 - 1870
  • [9] Antiandrogen monotherapy in patients with localized or locally advanced prostate cancer: final results from the bicalutamide Early Prostate Cancer programme at a median follow-up of 9.7 years
    Iversen, Peter
    McLeod, David G.
    See, William A.
    Morris, Thomas
    Armstrong, Jon
    Wirth, Manfred P.
    [J]. BJU INTERNATIONAL, 2010, 105 (08) : 1074 - 1081
  • [10] Bicalutamide 150 mg in addition to standard care significantly improves prostate specific antigen progression-free survival in patients with early, non-metastatic prostate cancer: Median 5.4 years' follow-up
    See, WA
    Iversen, P
    McLeod, DG
    Wirth, MP
    Carroll, K
    Morris, T
    Morris, CD
    [J]. JOURNAL OF UROLOGY, 2004, 171 (04): : 280 - 281
12345